Lewy Body Dementia Market: Accelerating Growth and Pipeline Impact by 2034- DelveInsight | Cognition Therapeutics, KeifeRx, Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics

The Key Lewy Body Dementia Companies in the market include - KeifeRx, Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics, Cephalon, Athira Pharma, Ortho-McNeil Neurologics, Inc., H. Lundbeck A/S, Axovant Sciences Ltd., GE Healthcare, Aptinyx, NeuroActiva, Inc., CuraSen Therapeutics, Inc., ACADIA Pharmaceuticals Inc., and others.

DelveInsight's "Lewy Body Dementia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Lewy Body Dementia, historical and forecasted epidemiology as well as the Lewy Body Dementia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Lewy Body Dementia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lewy Body Dementia Market Forecast [https://www.delveinsight.com/sample-request/lewy-body-dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Lewy Body Dementia Market Report:

*
The Lewy Body Dementia market size was valued ~USD 670 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

*
In July 2025, Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company focused on developing therapies for neurodegenerative disorders, announced that Dr. James E. Galvin, MD, MPH, will present findings from the Phase 2 'SHIMMER' study evaluating zervimesine (CT1812) in dementia with Lewy bodies (DLB) during an oral session at the Alzheimer's Association International Conference (AAIC). Dr. Galvin, director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine, also served as the study director for the COG1201 SHIMMER trial (NCT05225415).

*
In June 2025, A philanthropic donor provided funding for Cognition Therapeutics' expanded access program for Zervimesine (CT1812), aimed at supporting patients with dementia with Lewy bodies (DLB).

*
In March 2025, CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biopharmaceutical company developing therapies for age-related neurological disorders, reported encouraging results from the initial 16 weeks of the extension phase of its Phase 2b RewinD-LB study, evaluating neflamapimod for the treatment of dementia with Lewy bodies (DLB).

*
In January 2025, C2N Diagnostics, LLC, a renowned organization recognized for its pioneering efforts in neurological diseases, is collaborating with The Michael J. Fox Foundation for Parkinson's Research (MJFF) to explore the links between neurodegenerative disorders, including Alzheimer's disease (AD) and neuronal -synuclein diseases (NSD) such as Parkinson's disease (PD), Lewy body dementia (LBD), and REM behavior disorder (RBD).

*
In January 2025, Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company focused on developing treatments for neurodegenerative disorders, announced that Dr. James E. Galvin, MD, MPH, will present topline findings from the 'SHIMMER' study on zervimesine (CT1812) for dementia with Lewy bodies at the International Lewy Body Dementia Conference (ILBDC). Dr. Galvin, the director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine, served as the study director and principal investigator for the SHIMMER study grant from the National Institute on Aging.

*
As per DelveInsight's 2024 analysis, approximately 12 million diagnosed prevalent cases of dementia were reported across the 7MM, with projections indicating a significant Compound Annual Growth Rate (CAGR) driven increase throughout the 2025- 2034 forecast period.

*
Secondary sources estimate that LBD impacts approximately 1.4 million individuals in the US, underscoring its significant prevalence and the growing need for targeted awareness and intervention strategies.

*
In 2024, Japan reported approximately 3 million diagnosed prevalent cases of dementia, with DLB accounting for around 150 thousand cases.

*
In the US, the prevalence of LBD among Medicare beneficiaries ranged from 0.90% to 0.83% between 2010 and 2016. Among 9,019 LBD cases, 53.2% were diagnosed with DLB and 46.8% with PDD.

*
According to DelveInsight's 2024 analysis, approximately 330 thousand diagnosed prevalent cases of DLB were reported in the US, emphasizing the significant disease burden in one of the world's key pharmaceutical markets.

*
According to DelveInsight's 2024 findings, approximately 190 thousand diagnosed prevalent cases of DLB were identified across the EU4 and the UK, with the UK accounting for the largest proportion, suggesting regional disparities in disease recognition or healthcare access.

*
In Japan, 2024 data showed that 54% of diagnosed prevalent DLB cases were male and 46% female, indicating a slight male predominance. This gender variation may reflect differences in disease susceptibility, diagnosis rates, or healthcare-seeking behavior.

*
Key Lewy Body Dementia Companies: KeifeRx, Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics, Cephalon, Athira Pharma, Ortho-McNeil Neurologics, Inc., H. Lundbeck A/S, Axovant Sciences Ltd., GE Healthcare, Aptinyx, NeuroActiva, Inc., CuraSen Therapeutics, Inc., ACADIA Pharmaceuticals Inc., and others

*
Key Lewy Body Dementia Therapies: Zervimesine, Nilotinib, E2027, Neflamapimod, K0706, RVT-101, CT1812, K0706, Irsenontrine, Donepezil, ATH-1017, Galantamine, Memantine, Nelotanserin, DatSCAN, NYX-458, N-831(Traneurocin), CST-103, CST-107, Pimavanserin, and others

*
The Lewy Body Dementia epidemiology based on gender analyzed that through various secondary studies it can be found that LBD more commonly affects males than females

*
The Lewy Body Dementia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lewy Body Dementia pipeline products will significantly revolutionize the Lewy Body Dementia market dynamics.

Lewy Body Dementia Overview

Lewy body dementia (LBD) is a progressive neurodegenerative disorder that affects cognitive abilities, motor function, and behavior. It is characterized by the accumulation of abnormal protein deposits called Lewy bodies in the brain. LBD encompasses two main types: dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD).

Get a Free sample for the Lewy Body Dementia Market Report:

https://www.delveinsight.com/report-store/lewy-body-dementia-market [https://www.delveinsight.com/report-store/lewy-body-dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Lewy Body Dementia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Lewy Body Dementia Epidemiology Segmentation:

The Lewy Body Dementia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Diagnosed Prevalent Cases of Dementia in the 7MM

*
Total Diagnosed Prevalent Cases of LBD in the 7MM

*
Gender-specific Diagnosed Prevalent Cases of LBD in the 7MM

*
Type-specific Diagnosed Prevalent Cases of LBD in the 7MM

Download the report to understand which factors are driving Lewy Body Dementia epidemiology trends @ Lewy Body Dementia Epidemiology Forecast [https://www.delveinsight.com/sample-request/lewy-body-dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Lewy Body Dementia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Lewy Body Dementia market or expected to get launched during the study period. The analysis covers Lewy Body Dementia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Lewy Body Dementia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Lewy Body Dementia Therapies and Key Companies

*
Zervimesine: Cognition Therapeutics

*
Nilotinib: KeifeRx

*
E2027: Eisai

*
Neflamapimod: EIP Pharma

*
K0706: Sun Pharma

*
RVT-101: Axovant Sciences Ltd.

*
CT1812: Cognition Therapeutics

*
K0706: Cephalon

*
Irsenontrine: Eisai Inc.

*
Donepezil: Eisai Co., Ltd.

*
ATH-1017: Athira Pharma

*
Galantamine: Ortho-McNeil Neurologics, Inc.

*
Memantine: H. Lundbeck A/S

*
Nelotanserin: Axovant Sciences Ltd.

*
DatSCAN: GE Healthcare

*
NYX-458: Aptinyx

*
N-831(Traneurocin): NeuroActiva, Inc.

*
CST-103, CST-107: CuraSen Therapeutics, Inc.

*
Pimavanserin: ACADIA Pharmaceuticals Inc.

Discover more about therapies set to grab major Lewy Body Dementia market share @ Lewy Body Dementia Treatment Market [https://www.delveinsight.com/sample-request/lewy-body-dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Lewy Body Dementia Market Strengths

*
Increasing research and development to understand the diversity of the disease might improve the diagnosis of LBD thereby resulting in a lucrative market opportunity.

*
Current treatments are effective in relieving the symptoms and improving the quality of life of the patients.

Lewy Body Dementia Market Opportunities

*
Several organizations are actively working to provide information and increase awareness of such disorders.

*
There is only one approved treatment option for LBD which opens a platform of new therapies to boost the market ofLBD.

*
The pipeline for PMM is narrow as there is limited R&D activity

Scope of the Lewy Body Dementia Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Lewy Body Dementia Companies: KeifeRx, Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics, Cephalon, Athira Pharma, Ortho-McNeil Neurologics, Inc., H. Lundbeck A/S, Axovant Sciences Ltd., GE Healthcare, Aptinyx, NeuroActiva, Inc., CuraSen Therapeutics, Inc., ACADIA Pharmaceuticals Inc., and others

*
Key Lewy Body Dementia Therapies: Zervimesine, Nilotinib, E2027, Neflamapimod, K0706, RVT-101, CT1812, K0706, Irsenontrine, Donepezil, ATH-1017, Galantamine, Memantine, Nelotanserin, DatSCAN, NYX-458, N-831(Traneurocin), CST-103, CST-107, Pimavanserin, and others

*
Lewy Body Dementia Therapeutic Assessment: Lewy Body Dementia current marketed and Lewy Body Dementia emerging therapies

*
Lewy Body Dementia Market Dynamics: Lewy Body Dementia market drivers and Lewy Body Dementia market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Lewy Body Dementia Unmet Needs, KOL's views, Analyst's views, Lewy Body Dementia Market Access and Reimbursement

To know more about Lewy Body Dementia companies working in the treatment market, visit @ Lewy Body Dementia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/lewy-body-dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Lewy Body Dementia Market Report Introduction

2. Executive Summary for Lewy Body Dementia

3. SWOT analysis of Lewy Body Dementia

4. Lewy Body Dementia Patient Share (%) Overview at a Glance

5. Lewy Body Dementia Market Overview at a Glance

6. Lewy Body Dementia Disease Background and Overview

7. Lewy Body Dementia Epidemiology and Patient Population

8. Country-Specific Patient Population of Lewy Body Dementia

9. Lewy Body Dementia Current Treatment and Medical Practices

10. Lewy Body Dementia Unmet Needs

11. Lewy Body Dementia Emerging Therapies

12. Lewy Body Dementia Market Outlook

13. Country-Wise Lewy Body Dementia Market Analysis (2020-2034)

14. Lewy Body Dementia Market Access and Reimbursement of Therapies

15. Lewy Body Dementia Market Drivers

16. Lewy Body Dementia Market Barriers

17. Lewy Body Dementia Appendix

18. Lewy Body Dementia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lewy-body-dementia-market-accelerating-growth-and-pipeline-impact-by-2034-delveinsight-cognition-therapeutics-keiferx-eisai-eip-pharma-sun-pharma-axovant-sciences-ltd-cognition-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.